^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

surzebiclimab (BGB-A425)

i
Other names: BGB-A425, BGBA425, BGB A425
Associations
Company:
BeiGene
Drug class:
TIM-3 inhibitor
Associations
2ms
BGB-900-102: Study of BGB-A425 and LBL-007 in Combination with Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=358, Recruiting, BeiGene | Trial completion date: Dec 2027 --> Apr 2025 | Trial primary completion date: Mar 2026 --> Apr 2025
Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab-jsgr) • LBL-007 • surzebiclimab (BGB-A425)
6ms
BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov)
P3, N=300, Enrolling by invitation, BeiGene | Trial completion date: Aug 2024 --> Dec 2026 | Trial primary completion date: Aug 2024 --> Dec 2026
Trial completion date • Trial primary completion date • Metastases
|
temozolomide • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib) • Partruvix (pamiparib) • Ziihera (zanidatamab-hrii) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217) • sitravatinib (MGCD516) • BGB-15025 • BGB-A445 • LBL-007 • surzebiclimab (BGB-A425)
12ms
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab-jsgr) • LBL-007 • surzebiclimab (BGB-A425)
over1year
Enrollment open • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab-jsgr) • LBL-007 • surzebiclimab (BGB-A425)
over1year
New P2 trial • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab-jsgr) • LBL-007 • surzebiclimab (BGB-A425)
2years
BGB-900-102: Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=358, Recruiting, BeiGene | N=162 --> 358 | Trial completion date: Jan 2024 --> Dec 2027 | Trial primary completion date: Jul 2023 --> Mar 2026
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab-jsgr) • LBL-007 • surzebiclimab (BGB-A425)
3years
Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=162, Recruiting, BeiGene | Trial completion date: Sep 2023 --> Jan 2024 | Trial primary completion date: Mar 2023 --> Jul 2023
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab-jsgr) • surzebiclimab (BGB-A425)
over3years
Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=162, Recruiting, BeiGene | Trial completion date: Dec 2021 --> Sep 2023 | Trial primary completion date: Jun 2021 --> Mar 2023
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
Tevimbra (tislelizumab-jsgr) • surzebiclimab (BGB-A425)